Do analysts prefer BON or ADXS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bon Natural Life 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Ayala Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable earnings & valuation, BON or ADXS?

Bon Natural Life has higher revenue and earnings than Ayala Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bon Natural Life $18.67M 0.51 -$2M N/A N/A Ayala Pharmaceuticals $3.24M 11.05 -$48.07M -$5.02 N/A

Is BON or ADXS more profitable?

Company Net Margins Return on Equity Return on Assets Bon Natural Life N/A N/A N/A Ayala Pharmaceuticals N/A N/A N/A

Do analysts prefer GRML or BON?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Greenland Mines Ltd. Common Stock 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Bon Natural Life 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings & valuation, GRML or BON?

Bon Natural Life has higher revenue and earnings than Greenland Mines Ltd. Common Stock. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Greenland Mines Ltd. Common Stock N/A N/A -$10.55M -$0.32 N/A Bon Natural Life $18.67M 0.51 -$2M N/A N/A

Is GRML or BON more profitable?

Bon Natural Life's return on equity of 0.00% beat Greenland Mines Ltd. Common Stock's return on equity. Company Net Margins Return on Equity Return on Assets Greenland Mines Ltd. Common Stock N/A -109.40% -98.80% Bon Natural Life N/A N/A N/A

Do analysts prefer ALGS or BON?

Aligos Therapeutics presently has a consensus target price of $38.50, suggesting a potential upside of 588.73%. Given Aligos Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Aligos Therapeutics is more favorable than Bon Natural Life. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aligos Therapeutics 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.86 Bon Natural Life 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation and earnings, ALGS or BON?

Bon Natural Life has higher revenue and earnings than Aligos Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aligos Therapeutics $2.19M 15.80 -$24.19M -$8.69 N/A Bon Natural Life $18.67M 0.51 -$2M N/A N/A

Do analysts recommend BON or SNTI?

Senti Biosciences has a consensus target price of $10.00, indicating a potential upside of 834.58%. Given Senti Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Senti Biosciences is more favorable than Bon Natural Life. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bon Natural Life 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Senti Biosciences 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.75

Which has better valuation & earnings, BON or SNTI?

Bon Natural Life has higher revenue and earnings than Senti Biosciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bon Natural Life $18.67M 0.51 -$2M N/A N/A Senti Biosciences $20K 1,666.53 -$61.44M -$1.92 N/A

Is BON or SNTI more profitable?

Bon Natural Life's return on equity of 0.00% beat Senti Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Bon Natural Life N/A N/A N/A Senti Biosciences N/A -532.05% -103.35%

Do analysts rate ZYBT or BON?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zhengye Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Bon Natural Life 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings and valuation, ZYBT or BON?

Bon Natural Life has higher revenue and earnings than Zhengye Biotechnology. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zhengye Biotechnology $16.64M 1.84 -$9.98M N/A N/A Bon Natural Life $18.67M 0.51 -$2M N/A N/A

Is ZYBT or BON more profitable?

Company Net Margins Return on Equity Return on Assets Zhengye Biotechnology N/A N/A N/A Bon Natural Life N/A N/A N/A

Bon Natural Life (BON) Competitors

$1.18 0.00 (0.00%)

Closing price 07/2/2026 03:51 PM Eastern

Extended Trading

$1.19 +0.01 (+0.85%)

As of 07/2/2026 07:55 PM Eastern

Compare

BON vs. ADXS, GRML, ALGS, SNTI, and ZYBT

Should you buy Bon Natural Life stock or one of its competitors? MarketBeat compares Bon Natural Life with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Bon Natural Life include Ayala Pharmaceuticals (ADXS), Greenland Mines Ltd. Common Stock (GRML), Aligos Therapeutics (ALGS), Senti Biosciences (SNTI), and Zhengye Biotechnology (ZYBT). These companies are all part of the "pharmaceutical products" industry.

How does Bon Natural Life compare to Ayala Pharmaceuticals?

Bon Natural Life (NASDAQ:BON) and Ayala Pharmaceuticals (NASDAQ:ADXS) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership.

Bon Natural Life has a beta of -0.17, suggesting that its share price is 117% less volatile than the broader market. Comparatively, Ayala Pharmaceuticals has a beta of 1.75, suggesting that its share price is 75% more volatile than the broader market.

In the previous week, Ayala Pharmaceuticals had 1 more articles in the media than Bon Natural Life. MarketBeat recorded 1 mentions for Ayala Pharmaceuticals and 0 mentions for Bon Natural Life. Bon Natural Life's average media sentiment score of 0.00 equaled Ayala Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Bon Natural Life	Neutral
Ayala Pharmaceuticals	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bon Natural Life	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Ayala Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

0.6% of Bon Natural Life shares are held by institutional investors. Comparatively, 7.2% of Ayala Pharmaceuticals shares are held by institutional investors. 26.5% of Bon Natural Life shares are held by company insiders. Comparatively, 0.6% of Ayala Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Bon Natural Life has higher revenue and earnings than Ayala Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bon Natural Life	$18.67M	0.51	-$2M	N/A	N/A
Ayala Pharmaceuticals	$3.24M	11.05	-$48.07M	-$5.02	N/A

Company	Net Margins	Return on Equity	Return on Assets
Bon Natural Life	N/A	N/A	N/A
Ayala Pharmaceuticals	N/A	N/A	N/A

Summary

Bon Natural Life and Ayala Pharmaceuticals tied by winning 4 of the 8 factors compared between the two stocks.

How does Bon Natural Life compare to Greenland Mines Ltd. Common Stock?

Greenland Mines Ltd. Common Stock (NASDAQ:GRML) and Bon Natural Life (NASDAQ:BON) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, risk, valuation, analyst recommendations, media sentiment and institutional ownership.

Bon Natural Life's return on equity of 0.00% beat Greenland Mines Ltd. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Greenland Mines Ltd. Common Stock	N/A	-109.40%	-98.80%
Bon Natural Life	N/A	N/A	N/A

In the previous week, Greenland Mines Ltd. Common Stock had 2 more articles in the media than Bon Natural Life. MarketBeat recorded 2 mentions for Greenland Mines Ltd. Common Stock and 0 mentions for Bon Natural Life. Greenland Mines Ltd. Common Stock's average media sentiment score of 0.30 beat Bon Natural Life's score of 0.00 indicating that Greenland Mines Ltd. Common Stock is being referred to more favorably in the media.

Company	Overall Sentiment
Greenland Mines Ltd. Common Stock	Neutral
Bon Natural Life	Neutral

Greenland Mines Ltd. Common Stock has a beta of 7.05, indicating that its stock price is 605% more volatile than the broader market. Comparatively, Bon Natural Life has a beta of -0.17, indicating that its stock price is 117% less volatile than the broader market.

Bon Natural Life has higher revenue and earnings than Greenland Mines Ltd. Common Stock.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Greenland Mines Ltd. Common Stock	N/A	N/A	-$10.55M	-$0.32	N/A
Bon Natural Life	$18.67M	0.51	-$2M	N/A	N/A

20.1% of Greenland Mines Ltd. Common Stock shares are held by institutional investors. Comparatively, 0.6% of Bon Natural Life shares are held by institutional investors. 11.3% of Greenland Mines Ltd. Common Stock shares are held by insiders. Comparatively, 26.5% of Bon Natural Life shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Greenland Mines Ltd. Common Stock	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Bon Natural Life	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Bon Natural Life beats Greenland Mines Ltd. Common Stock on 5 of the 9 factors compared between the two stocks.

How does Bon Natural Life compare to Aligos Therapeutics?

Aligos Therapeutics (NASDAQ:ALGS) and Bon Natural Life (NASDAQ:BON) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, media sentiment, risk, dividends and earnings.

Bon Natural Life has higher revenue and earnings than Aligos Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aligos Therapeutics	$2.19M	15.80	-$24.19M	-$8.69	N/A
Bon Natural Life	$18.67M	0.51	-$2M	N/A	N/A

Bon Natural Life has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -1,919.68%. Bon Natural Life's return on equity of 0.00% beat Aligos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aligos Therapeutics	-1,919.68%	-139.47%	-90.88%
Bon Natural Life	N/A	N/A	N/A

Aligos Therapeutics has a beta of 2.26, meaning that its share price is 126% more volatile than the broader market. Comparatively, Bon Natural Life has a beta of -0.17, meaning that its share price is 117% less volatile than the broader market.

60.4% of Aligos Therapeutics shares are held by institutional investors. Comparatively, 0.6% of Bon Natural Life shares are held by institutional investors. 7.8% of Aligos Therapeutics shares are held by insiders. Comparatively, 26.5% of Bon Natural Life shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Aligos Therapeutics presently has a consensus target price of $38.50, suggesting a potential upside of 588.73%. Given Aligos Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Aligos Therapeutics is more favorable than Bon Natural Life.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aligos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Bon Natural Life	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Aligos Therapeutics had 1 more articles in the media than Bon Natural Life. MarketBeat recorded 1 mentions for Aligos Therapeutics and 0 mentions for Bon Natural Life. Aligos Therapeutics' average media sentiment score of 0.00 equaled Bon Natural Life'saverage media sentiment score.

Company	Overall Sentiment
Aligos Therapeutics	Neutral
Bon Natural Life	Neutral

Summary

Aligos Therapeutics beats Bon Natural Life on 8 of the 14 factors compared between the two stocks.

How does Bon Natural Life compare to Senti Biosciences?

Bon Natural Life (NASDAQ:BON) and Senti Biosciences (NASDAQ:SNTI) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, risk, profitability, media sentiment, analyst recommendations, institutional ownership and valuation.

Bon Natural Life has higher revenue and earnings than Senti Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bon Natural Life	$18.67M	0.51	-$2M	N/A	N/A
Senti Biosciences	$20K	1,666.53	-$61.44M	-$1.92	N/A

Bon Natural Life's return on equity of 0.00% beat Senti Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bon Natural Life	N/A	N/A	N/A
Senti Biosciences	N/A	-532.05%	-103.35%

Senti Biosciences has a consensus target price of $10.00, indicating a potential upside of 834.58%. Given Senti Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Senti Biosciences is more favorable than Bon Natural Life.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bon Natural Life	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Senti Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75

0.6% of Bon Natural Life shares are owned by institutional investors. Comparatively, 25.7% of Senti Biosciences shares are owned by institutional investors. 26.5% of Bon Natural Life shares are owned by company insiders. Comparatively, 3.1% of Senti Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Senti Biosciences had 1 more articles in the media than Bon Natural Life. MarketBeat recorded 1 mentions for Senti Biosciences and 0 mentions for Bon Natural Life. Senti Biosciences' average media sentiment score of 0.67 beat Bon Natural Life's score of 0.00 indicating that Senti Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Bon Natural Life	Neutral
Senti Biosciences	Positive

Bon Natural Life has a beta of -0.17, meaning that its stock price is 117% less volatile than the broader market. Comparatively, Senti Biosciences has a beta of 2.04, meaning that its stock price is 104% more volatile than the broader market.

Summary

Senti Biosciences beats Bon Natural Life on 9 of the 14 factors compared between the two stocks.

How does Bon Natural Life compare to Zhengye Biotechnology?

Zhengye Biotechnology (NASDAQ:ZYBT) and Bon Natural Life (NASDAQ:BON) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, risk, profitability, analyst recommendations, earnings and institutional ownership.

0.6% of Bon Natural Life shares are owned by institutional investors. 26.5% of Bon Natural Life shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zhengye Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Bon Natural Life	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Bon Natural Life has higher revenue and earnings than Zhengye Biotechnology.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zhengye Biotechnology	$16.64M	1.84	-$9.98M	N/A	N/A
Bon Natural Life	$18.67M	0.51	-$2M	N/A	N/A

Company	Net Margins	Return on Equity	Return on Assets
Zhengye Biotechnology	N/A	N/A	N/A
Bon Natural Life	N/A	N/A	N/A

In the previous week, Zhengye Biotechnology's average media sentiment score of 0.00 equaled Bon Natural Life'saverage media sentiment score.

Company	Overall Sentiment
Zhengye Biotechnology	Neutral
Bon Natural Life	Neutral

Zhengye Biotechnology has a beta of -2.18, suggesting that its stock price is 318% less volatile than the broader market. Comparatively, Bon Natural Life has a beta of -0.17, suggesting that its stock price is 117% less volatile than the broader market.

Summary

Bon Natural Life beats Zhengye Biotechnology on 5 of the 6 factors compared between the two stocks.

Get Bon Natural Life News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BON vs. The Competition

Export

Metric	Bon Natural Life	CONSM PD Industry	Discretionary Sector	NASDAQ Exchange
Market Cap	$9.58M	$1.52B	$7.36B	$12.48B
Dividend Yield	N/A	4.84%	3.03%	6.52%
P/E Ratio	N/A	9.11	20.70	24.70
Price / Sales	0.51	3.28	4.20	99.42
Price / Cash	N/A	16.92	15.55	57.09
Price / Book	0.17	1.46	3.84	6.46
Net Income	-$2M	$61.01M	$247.92M	$337.01M
7 Day Performance	4.34%	1.18%	0.46%	1.69%
1 Month Performance	-5.68%	9.07%	2.55%	3.81%
1 Year Performance	-21.40%	0.25%	0.53%	23.90%

Bon Natural Life Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BON Bon Natural Life	0.8697 of 5 stars	$1.18 flat	N/A	-21.4%	$9.58M	$18.67M	N/A	100	Gap Down
ADXS Ayala Pharmaceuticals	N/A	$0.60 flat	N/A	N/A	$35.79M	$3.24M	N/A	20
GRML Greenland Mines Ltd. Common Stock	0.6351 of 5 stars	$0.26 flat	N/A	-79.6%	$35.35M	N/A	N/A	5	Gap Up
ALGS Aligos Therapeutics	2.3362 of 5 stars	$5.57 flat	$38.50 +591.2%	-29.7%	$34.48M	$2.19M	N/A	90	News Coverage
SNTI Senti Biosciences	2.6954 of 5 stars	$1.09 flat	$10.00 +817.4%	-52.8%	$33.95M	$20K	N/A	4	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BON) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bon Natural Life (BON) Competitors

BON vs. ADXS, GRML, ALGS, SNTI, and ZYBT

How does Bon Natural Life compare to Ayala Pharmaceuticals?

Summary

How does Bon Natural Life compare to Greenland Mines Ltd. Common Stock?

Summary

How does Bon Natural Life compare to Aligos Therapeutics?

Summary

How does Bon Natural Life compare to Senti Biosciences?

Summary

How does Bon Natural Life compare to Zhengye Biotechnology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BON vs. The Competition

Bon Natural Life Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bon Natural Life (BON) Competitors

BON vs. ADXS, GRML, ALGS, SNTI, and ZYBT

How does Bon Natural Life compare to Ayala Pharmaceuticals?

Which has more volatility and risk, BON or ADXS?

Does the media refer more to BON or ADXS?

Do analysts prefer BON or ADXS?

Do institutionals and insiders believe in BON or ADXS?

Which has preferable earnings & valuation, BON or ADXS?

Is BON or ADXS more profitable?

Summary

How does Bon Natural Life compare to Greenland Mines Ltd. Common Stock?

Is GRML or BON more profitable?

Does the media refer more to GRML or BON?

Which has more volatility & risk, GRML or BON?

Which has higher earnings & valuation, GRML or BON?

Do institutionals and insiders believe in GRML or BON?

Do analysts prefer GRML or BON?

Summary

How does Bon Natural Life compare to Aligos Therapeutics?

Which has higher valuation and earnings, ALGS or BON?

Is ALGS or BON more profitable?

Which has more volatility & risk, ALGS or BON?

Do institutionals and insiders believe in ALGS or BON?

Do analysts prefer ALGS or BON?

Does the media refer more to ALGS or BON?

Summary

How does Bon Natural Life compare to Senti Biosciences?

Which has better valuation & earnings, BON or SNTI?

Is BON or SNTI more profitable?

Do analysts recommend BON or SNTI?

Do institutionals & insiders have more ownership in BON or SNTI?

Does the media prefer BON or SNTI?

Which has more volatility & risk, BON or SNTI?

Summary

How does Bon Natural Life compare to Zhengye Biotechnology?

Do institutionals and insiders have more ownership in ZYBT or BON?

Do analysts rate ZYBT or BON?

Which has preferable earnings and valuation, ZYBT or BON?

Is ZYBT or BON more profitable?

Does the media prefer ZYBT or BON?

Which has more risk & volatility, ZYBT or BON?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BON vs. The Competition

Bon Natural Life Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools